Monitor the definitive proxy statement for the 2026 Annual Meeting when filed for any shareholder proposals or director nominations that could signal activist interest. The accelerated timeline (meeting ~60 days after the 2025 meeting) compresses the window for shareholder engagement.
Price Chart
Executive Summary
NRx Pharmaceuticals filed an 8-K to announce the 2026 Annual Meeting of Stockholders, scheduled for December 17, 2026, with a record date of October 28, 2026. The filing sets revised deadlines for stockholder proposals and director nominations due to the meeting date being more than 30 days before the anniversary of the 2025 Annual Meeting. This is a routine procedural filing with no material financial or operational impact.
Key Facts
- 2026 Annual Meeting set for December 17, 2026, at 10:00 a.m. ET in virtual-only format
- Record date for voting is October 28, 2026
- Deadline for Rule 14a-8 stockholder proposals is October 25, 2026
- Deadline for advance notice of stockholder proposals and director nominations is October 25, 2026
- Deadline for Rule 14a-19 universal proxy notice is October 26, 2026
Financial Impact
No financial impact — this is a procedural meeting scheduling announcement
Risk Factors
- No material risks identified — this is a routine administrative filing
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032828 |
| Document: 0001437749-26-032828-index-headers.html | 0001437749-26-032828 |
| Document: 0001437749-26-032828-index.html | 0001437749-26-032828 |
| Document: 0001437749-26-032828.txt | 0001437749-26-032828 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | 8-K | $2.63 | awaiting T+60 | awaiting T+60 | $2.69 (+2.28%) |
Oct 5, 2026 22d ago | 8-K | $2.94 | awaiting T+60 | awaiting T+60 | $2.69 (−8.50%) |
Sep 15, 2026 6w ago | 8-K | $3.35 | awaiting T+60 | awaiting T+60 | $2.69 (−19.70%) |
Sep 14, 2026 6w ago | 8-K | $3.49 | awaiting T+60 | awaiting T+60 | $2.69 (−22.92%) |
Aug 17, 2026 10w ago | 8-K | $3.43 | awaiting T+60 | awaiting T+60 | $2.69 (−21.57%) |
Aug 17, 2026 10w ago | Press Release | $3.43 | awaiting T+60 | awaiting T+60 | $2.69 (−21.57%) |
Aug 7, 2026 11w ago | 8-K | $3.58 | awaiting T+60 | awaiting T+60 | $2.69 (−24.86%) |
Jul 22, 2026 13w ago | 8-K | $4.48 $2.71 | ▼ −39.51% | ▼ −42.77% | $2.69 (−39.96%) |
Jun 22, 2026 18w ago | Press Release | $3.90 $3.40 | ▼ −12.82% | ▼ −14.57% | $2.69 (−31.03%) |
Jun 5, 2026 20w ago | Press Release | $4.14 $3.48 | ▼ −15.94% | ▼ −19.94% | $2.69 (−35.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers